Article · Wikipedia archive · Last revised Jun 22, 2026

PL-6983

PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials. Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models. The drug has reportedly been in pre-clinical development for all medical indications since 2008. Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983." The chemical structure of PL-6983 has yet to be made public.

Last revised
Jun 22, 2026
Read time
≈ 1 min
Length
297 w
Citations
8
Source
Wikipedia ↗
PL-6983
Clinical data
Routes of
administration		Subcutaneous injection
Drug classMelanocortin MC4 receptor agonist
Identifiers
CAS Number
PubChem SID

PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.12 It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.12 Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.12 The drug has reportedly been in pre-clinical development for all medical indications since 2008.3 Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."4 The chemical structure of PL-6983 has yet to be made public.

See also

See also

References

References

  1. Simon JA (July 2009). Mitchner N (ed.). "Opportunities for intervention in HSDD" (PDF). The Journal of Family Practice. 58 (7 Suppl Hypoactive): S26–30. PMID 19825316. Archived from the original (PDF) on 2015-05-18. Retrieved 2015-05-14.
  2. Krychman ML, Finestone S (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN 978-1-4496-1936-7.
  3. "Research programme: sexual dysfunction therapy - Palatin Technologies". AdisInsight. Springer Nature Switzerland AG. Retrieved 2019-06-06.
  4. "Palatin Technologies - PL-6983 for Female Sexual Dysfunction". 2015-05-26. Archived from the original on 2015-05-26.
External links